New perspectives on the role of vitiligo in immune responses to melanoma - Wikidata - wikimedia - TriplyDB

New perspectives on the role of vitiligo in immune responses to melanoma

New perspectives on the role of vitiligo in immune responses to melanoma

http://www.wikidata.org/entity/Q26996799

about

Melanoma-associated leukoderma - immunology in black and white?Toxicities of Immunotherapy for the Practitioner Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma Combination immunotherapy for high-risk resected and metastatic melanoma patients Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo.Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma.Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival Immunogenicity of targeted lentivectors.Do inflammatory pathways drive melanomagenesis?Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma.Regression of nevi in a melanoma patient treated with interferon.Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells.Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study.The Pharmacology of T Cell Therapies.Immunotherapy in mucosal melanoma: a case report and review of the literature.Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events.

P2860

Q26850001-82541910-C270-431D-B1ED-A5A1C745BBA0 Q27008140-85FAB776-90E8-4B36-9BE8-4D66B1DFA0E4 Q28067023-2CD0E3FE-99DA-45A4-AB75-75898BC84668 Q33737498-5FC26D13-F73F-4C6F-8FDE-7A5C7F488AAD Q34352772-85727C37-5024-45A1-9832-6809B02A9DCF Q34386621-191737F3-8594-4D29-BCAE-12553B66031A Q35627237-94EA6486-B6CD-49D1-B7E2-DA0675C83256 Q36339260-A5C7325C-D8C2-4435-9557-04E4DFD7285B Q36505754-AD7652F0-F4FD-45B7-B3D9-2C78AFBC4978 Q37088617-354DBDC1-D2CE-4F3E-80D8-489941658BBB Q37299271-BAC74F3F-540C-45D1-9A02-1777FBAC572C Q37718447-87DFA2A4-CD17-47B7-988D-59BD433902DA Q38231601-ED2984AA-91DF-4134-BB25-BD4C3AA082CB Q38916814-413B2D68-F969-4C56-9F3F-E994BCA00EF9 Q40148698-ACCD0125-03EF-424A-BD8C-A59B5F920880 Q41010063-72076D5D-7C88-477B-B518-14FCEAE8CC74 Q42609189-26F348A2-7ECB-4F62-8A82-EB32ED8F6452 Q42610971-CB8C1C64-A994-439F-A2AB-BFD8A7577DC0 Q43025486-7F629536-2BC7-4D9A-ABCE-6F03A08187E6 Q53039229-1656E4E1-EC2D-47F0-8E4D-FEC3EA5C23B6 Q54985631-E8E18806-A47B-4F80-806B-1284C4761457 Q55053720-D6A34258-155C-4F85-B742-A47BF648EB80 Q55243058-01DEEC54-6148-4C83-A858-5EF016BD9878

P2860

New perspectives on the role of vitiligo in immune responses to melanoma

http://www.wikidata.org/entity/Q26996799

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

New perspectives on the role of vitiligo in immune responses to melanoma

@ast

New perspectives on the role of vitiligo in immune responses to melanoma

@en

New perspectives on the role of vitiligo in immune responses to melanoma

@nl

type

label

New perspectives on the role of vitiligo in immune responses to melanoma

@ast

New perspectives on the role of vitiligo in immune responses to melanoma

@en

New perspectives on the role of vitiligo in immune responses to melanoma

@nl

prefLabel

New perspectives on the role of vitiligo in immune responses to melanoma

@ast

New perspectives on the role of vitiligo in immune responses to melanoma

@en

New perspectives on the role of vitiligo in immune responses to melanoma

@nl

P1433

Q26996799-80177F4D-0FB3-4824-9C43-160B9BA53662

P1476

Q26996799-0887C41D-C11D-4A9D-8345-489C18FE6D5A

P2093

Q26996799-0A6E1625-C621-49E0-A78D-3EF9458F14F3

Q26996799-39FD0213-51C6-4932-AD58-29541F4FF4F2

P275

Q26996799-2A7BEBD4-09BB-474F-949B-C60B14203D0B

P2860

Q26996799-036ACF38-5928-4986-947A-9B3E9571EEFF

Q26996799-045E7D2C-0F2B-4094-B118-2DD02F467757

Q26996799-04D4AE01-A521-4B94-A121-A0C72AD85618

Q26996799-07EA97B6-D0B6-4279-9B73-33CE9D1930A9

Q26996799-0F2E1341-8E18-4987-B179-2C55F245A125

Q26996799-10338A3E-C866-415F-8D60-DE936A4CF783

Q26996799-1EA0785E-C90F-48EB-9DAC-3DDEA5CFB3F8

Q26996799-1F034F36-49AD-40E3-A9B4-55ACE57FCEE6

Q26996799-243F05B9-FA3D-4948-B562-DED46B9DFABA

Q26996799-28913894-CD4A-45EF-A14C-F3C23693D631

P304

Q26996799-15128EF6-C837-44EC-8D4C-F13E0F073D73

P31

Q26996799-9208BE14-9C2F-44E0-BE20-49E63556DB07

Q26996799-99CFD123-746A-452D-B0F9-B0F32DC79077

P3181

Q26996799-58234176-3B72-4FAD-90B9-6040756329DE

P356

Q26996799-09EDD404-915D-4BE1-A016-B6A20147AE9D

P407

Q26996799-F382F022-6987-4147-9386-7CC0692FD1BE

P433

Q26996799-C2180EB4-F630-4DB6-9ACE-1CD83A728EBE

P478

Q26996799-B8043F14-7389-42D2-9466-27CB456AB74D

P5008

Q26996799-0DDC538A-18E1-43CF-9FE1-B2C2FC743E03

P577

Q26996799-11588EEB-E6E3-452E-8314-7A350853E9C8

Q26996799-CFF5DEDF-5F6B-457E-8C75-352093B05435

P5875

Q26996799-D260A645-03ED-4F14-A883-A4CA28293309

P698

Q26996799-BB3E3EB6-0BD6-48E4-97D2-550B6078FB70

P921

Q26996799-2B53BE4E-F74F-4649-9297-463EA6073DFE

Q26996799-D171E54A-D95B-4491-994F-ABEC3D2FC3FF

Q26996799-FB7362CB-2AC4-4F1E-B79F-87784652EEDA

P932

Q26996799-DCAE10A9-00CC-49C0-B5FE-3D9397D0F69E

P3181

P356

P1433

P1476

New perspectives on the role of vitiligo in immune responses to melanoma

@en

P2093

Katelyn T. Byrne

http://www.w3.org/2001/XMLSchema#string

Mary Jo Turk

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Tumor-specific Th17-polarized cells eradicate large established melanoma

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy

Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.

Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes.

P304

684-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4652558

http://www.w3.org/2001/XMLSchema#string

P356

10.18632/ONCOTARGET.323

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51632146

http://www.w3.org/2001/XMLSchema#string

P698

21911918

http://www.w3.org/2001/XMLSchema#string

P921

P932

3248219

http://www.w3.org/2001/XMLSchema#string